AffyImmune Announces Presentation on Affinity-Tuned CAR T Therapy AIC100 at ASCO 2024
24 Apr 2024
Phase 1ASCOCell TherapyImmunotherapyClinical Result
NATICK, Mass.--(BUSINESS WIRE)-- AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced an abstract detailing its affinity-tuned CAR T therapy AIC100 will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, held May 31-June 4, at McCormick Place Convention Center in Chicago, IL.
“We look forward to presenting our preliminary data at ASCO, and to provide initial safety and efficacy results from our Phase 1 trial evaluating AIC100 CAR T therapy in patients with advanced thyroid cancers,” said Matt Britz, CEO, AffyImmune. “These results mark significant progress, as we continue to advance our affinity-tuned CAR T therapies for patients with unmet medical need.”
Presentation Details:
Title: Safety and Efficacy of AIC100 Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients with Advanced Thyroid Cancers: results from the phase 1 study
Presenter: Dr. Samer Ali Srour, University of Texas MD Anderson Cancer Center
Session Type: Poster Session– Head and Neck Cancer
Abstract Number: 6112
Date and Time: June 2, 2024: 9:00 AM - 12:00 PM CDT
Location: McCormick Place Convention Center in Chicago, Illinois
About AffyImmune Therapeutics
AffyImmune is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies to transform the lives of patients with cancer. The Company’s proprietary technology utilizing ICAM-1/LFA-1 interaction can potentially address all critical CAR T challenges such as toxicity, antigen loss, T-cell trafficking and exhaustion, while also allowing in vivo tracking of the CAR T cells. Its lead candidate, AIC100, is an ICAM-1-directed CAR T therapy being developed for patients with advanced thyroid cancer. AffyImmune is developing a focused pipeline of therapeutics targeting ICAM-1 in oncologic indications with high unmet medical need. AffyImmune is based in Natick, MA. For more information, visit .
View source version on businesswire.com:
Contacts
Media
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744
Source: AffyImmune Therapeutics, Inc.
View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.